Trial Patients Show Less Activity, More Fibrosis
Researchers report that patients screened for MASH trials now present with less disease activity but more advanced liver scarring.
Global Diabetes News
Coverage here follows diabetes — GLP-1 and other drug approvals, continuous glucose monitoring technology, diet and prevention research, Type 1 treatment advances and the prevalence data that describes how widely the condition affects populations globally. Reporting spans the clinical and the public health dimensions.
Recent news
November 7, 2026
Sweetened Soda Linked to Higher Diabetes RiskA large Australian study found artificially sweetened soda drinkers faced higher type 2 diabetes risk over nearly 14 years.
November 6, 2026
Study Finds Insulin Control Dips During FlightsA preliminary study of adults with type 1 diabetes using automated insulin delivery found lower glucose control while flying than on the ground.
November 6, 2026
Pilot Study Outlines Cataract Surgery Protocol for DiabetesA multicenter pilot study published in Clinical Ophthalmology evaluates a structured evaluation and care protocol for cataract surgery in patients with diabetes.
November 5, 2026
Abbott Brings Plosbrio Diabetes Drug to Asia PacificAbbott will commercialise Novo's semaglutide brand Plosbrio across Singapore and other Asia Pacific markets, following a related launch in India.
November 4, 2026
Skin Clearance Tops Psoriasis Treatment ChoicesA multicountry study found patients with systemic-eligible psoriasis weigh skin clearance most heavily when choosing therapy.
November 3, 2026
Eye Asymmetry Signals Diabetic Retinopathy SeverityA retrospective study of 221 patients links differences between left and right eyes to the progression of diabetic retinopathy.
November 3, 2026
Blood Group B Linked to Higher Diabetes RiskA review in BMC Medicine found people with blood group B face a 28 percent higher relative risk of type 2 diabetes, the only blood-group link among 270 reviewed to meet top evidence standards.
November 3, 2026
BioLife to Present Oral Peptide Technology in LondonBioLife Products Limited will showcase its oral delivery platform for peptide medicines at the LSX Investival Showcase on November 16, 2026.
November 3, 2026
Obefazimod Shows Quick Relief in Colitis TrialA subgroup analysis of Phase 3 ABTECT data found symptom improvement within one week of treatment in ulcerative colitis patients.
November 3, 2026
Duchess Visits Antigua for Eye Health SummitThe Duchess of Edinburgh toured an eye care unit and addressed the Global Summit for Eye Health in Antigua and Barbuda.
More in Diabetes
The beat runs across drug approval and effectiveness data, glucose monitoring technology advances, dietary and lifestyle intervention research, Type 1 diabetes mechanism and treatment studies, insulin pricing and access policy and the prevalence surveys that document how diabetes rates are changing across populations and geographies. GLP-1 drugs have created a convergence between diabetes and weight loss coverage, since the same medications carry approvals and data in both conditions, requiring coverage to track clinical evidence, regulatory status and insurance access simultaneously across intersecting patient populations. Insulin pricing and access has been a sustained policy and accountability subject in diabetes coverage, since the gap between the cost of manufacturing insulin and the price charged to patients has been documented and debated at legislative, regulatory and judicial levels. Continuous glucose monitoring technology has shifted diabetes management coverage toward devices and data, with wearable sensors generating stories about accuracy, insurance coverage and the integration of glucose data into broader health monitoring systems that reach beyond the diabetes community.